Research may help doctors predict who gets long-term complications from Lyme disease

April 16, 2014

A team of scientists led by Johns Hopkins and Stanford University researchers has laid the groundwork for understanding how variations in immune responses to Lyme disease can contribute to the many different outcomes of this bacterial infection seen in individual patients. A report on the work appears online April 16 in PLOS One.

"Physicians have recognized for many years that Lyme disease is not a uniform disease process and can vary in outcomes," says Mark Soloski, Ph.D., a professor of medicine at the Johns Hopkins University School of Medicine and senior author of the report. "Our experiments have linked such differences to specific immune pathways controlled by elements of the immune system, which in turn might help us understand both the good immune processes that clear up the infection and the bad ones that cause injury and prolong symptoms. This could be a big step forward in managing this disease."

Lyme disease is caused by the bacterium Borrelia burgdorferi, which is transmitted to humans through the bite of infected ticks. The U.S. Centers for Disease Control and Prevention estimates that there are 300,000 new cases of Lyme disease a year. Symptoms can include fever, headache, fatigue and a characteristic circular, red skin rash called erythema migrans, which occurs early in the disease.

Arthritis, nervous system abnormalities and heart rhythm abnormalities can appear weeks or months after infection.

Although treatment with antibiotics usually restores pre-infection health within a few weeks, some patients develop post-treatment Lyme disease syndrome, whose symptoms include fatigue, pain or joint and muscle aches that can last for several months. The exact cause is not well understood, and the symptoms are difficult to treat, the researchers say.

In a bid to identify why symptoms persist in some patients and not others, the Johns Hopkins team searched for the biological "signature" of the early stages of Lyme disease by measuring the levels of immune system molecules, called cytokines, chemokines and acute phase makers—proteins released by the liver as part of the process of inflammation. These molecules, which are also called mediators, orchestrate the complex interactions of the immune system response to infection, including inflammation.

Specifically, the team studied levels of 58 cytokines and chemokines plus seven acute phase markers in blood from 44 patients diagnosed with Lyme disease and 23 healthy people used as controls for comparison.

The team's analysis identified two subsets of Lyme disease in patients in the acute (early) stage of infection—"mediator-high" and "mediator-low."

The levels of three chemokines in particular—CXCL9, CXCL10 and CCL19—were increased in the mediator-high group and returned to normal levels after antibiotic treatment and the disappearance of the rash. Chemokines are small signaling molecules that attach to specific sites, called receptors, on a certain type of immune cells. These three chemokines in particular guide a type of immune cell called T lymphocytes into tissues to aid in the clearance of infection. The movement of T cells from the bloodstream to the site of infection also contributes to inflammation, which can cause tissue injury, Soloski notes. There was also an increase in the acute phase proteins released by the liver, including CRP and serum amyloid A.

Lyme disease patients displaying high mediator levels at the initial pretreatment visit (acute disease) also had more severe symptoms, higher rates of bacterial antibody production, greater rates of elevated liver enzymes and low blood lymphocytes levels. Elevated levels of liver enzyme activity are common during infection and other diseases and may indicate that the liver is a site of infection during human Lyme disease.

Individuals in the mediator-low group appear to represent Lyme disease patients who failed to mount a vigorous immune response, the researchers reported.

The results of the study indicate that the levels of chemokines in the blood and the levels of their specific receptors on the T cells they stimulate might prove to be important biomarkers for Lyme disease, and they could be linked to specific symptoms of the disease, Soloski says. Biomarkers are biological characteristics or molecules whose levels in the body or tissues can be measured to identify a specific biological state or condition (e.g., disease or response to therapy).

Although the study wasn't specifically designed to learn about post-treatment Lyme disease syndrome, the authors speculate that the variations in the pattern of mediators they observed strongly influence whether particular patients will recover from Lyme disease or develop long-term post-treatment symptoms.

"This study gives us basic data that will help us look for evidence of prolonged inflammation after completion of therapy and might, in the long term, help us identify biomarkers that predict that a particular person will develop post-treatment Lyme syndrome," Soloski says. "And since the chemokines that were elevated are key to the movement of T cells, blocking them might prevent them from moving into tissues and prolonging inflammation. This is one of the long-term aims of our work."

Explore further: Test for persistent Lyme infection using live ticks shown safe in clinical study

Related Stories

Test for persistent Lyme infection using live ticks shown safe in clinical study

February 12, 2014
In a first-of-its-kind study for Lyme disease, researchers have used live, disease-free ticks to see if Lyme disease bacteria can be detected in people who continue to experience symptoms such as fatigue or arthritis after ...

Key to Lyme disease's locale may be found in the gut of a tick

January 16, 2014
The prevalence of Lyme disease varies greatly between different locales throughout the Northeast, even though the deer ticks that transmit Lyme bacterium are common throughout the entire region.

3Qs: A new path to curing chronic Lyme disease

April 11, 2014
Earlier this year, the Centers for Disease Control and Prevention projected the number of undiagnosed cases of Lyme disease to be 10-fold higher than previously believed. Of the newly identified 300,000 people infected each ...

Even after Lyme disease is gone, its remains may perpetuate inflammation

June 26, 2012
(Medical Xpress) -- Non-infectious proteins of the species of bacteria that causes Lyme disease can remain in the body for a long time after antibiotic therapy, and are capable of causing an inflammatory immune reaction that ...

New Lyme disease estimate: 300,000 cases a year

August 19, 2013
Health officials say Lyme disease is about 10 times more common than previously reported.

Recommended for you

Finish your antibiotics course? Maybe not, experts say

July 27, 2017
British disease experts on Thursday suggested doing away with the "incorrect" advice to always finish a course of antibiotics, saying the approach was fuelling the spread of drug resistance.

Co-infection with two common gut pathogens worsens malnutrition in mice

July 27, 2017
Two gut pathogens commonly found in malnourished children combine to worsen malnutrition and impair growth in laboratory mice, according to new research published in PLOS Pathogens.

Phase 3 trial confirms superiority of tocilizumab to steroids for giant cell arteritis

July 26, 2017
A phase 3 clinical trial has confirmed that regular treatment with tocilizumab, an inhibitor of interleukin-6, successfully reduced both symptoms of and the need for high-dose steroid treatment for giant cell arteritis, the ...

A large-scale 'germ trap' solution for hospitals

July 26, 2017
When an infectious airborne illness strikes, some hospitals use negative pressure rooms to isolate and treat patients. These rooms use ventilation controls to keep germ-filled air contained rather than letting it circulate ...

Researchers report new system to study chronic hepatitis B

July 25, 2017
Scientists from Princeton University's Department of Molecular Biology have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections. ...

Male hepatitis B patients suffer worse liver ailments, regardless of lifestyle

July 25, 2017
Why men with hepatitis B remain more than twice as likely to develop severe liver disease than women remains a mystery, even after a study led by a recent Drexel University graduate took lifestyle choices and environments ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.